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Key Points
•DLBCL patients re-
lapsing within 1 year of
auto-HCT, and more
importantly within
6 months of auto-HCT,
have worse outcomes.
• This study provides
benchmarking for fu-
ture trials of chimeric
antigen receptor T cells
and other agents eval-
uating PR-OS after
auto-HCT.
Outcomes for diffuse large B-cell lymphoma (DLBCL) patients relapsing after autologous
hematopoietic cell transplantation (auto-HCT) have been historically poor. We studied
outcomes of such patients using data from 4 transplantation centers. Eligibility criteria
included adult patients (age$18 years) with DLBCL experiencing disease relapse after auto-
HCT performed during 2006 to 2015. The time period was stratified into 2 eras (era 1, 2006-
2010; era 2, 2011-2015). The primary end point was postrelapse overall survival (PR-OS).
Secondary end points were factors prognostic of PR-OS. Of the 700 patients with DLBCL who
underwent auto-HCT, 248 (35%) relapsed after auto-HCT. Median PR-OS of all relapsed
DLBCL patients after auto-HCT (n5 228) was 9.8months (95% confidence interval [CI], 7-15).
Median PR-OS was significantly better for patients in complete (17.8 months; 95% CI, 7.9-
41.6) vs partial remission at auto-HCT (7.1 months; 95% CI, 5.4-11; P5 .01), those undergoing
auto-HCT .1 year (12.8 months; 95% CI, 7.6-24.9) vs #1 year after DLBCL diagnosis (6.3
months; 95% CI, 4.5-9.2; P 5 .01), and those with late (56.4 months; 95% CI, 23.7-‘) vs early
relapse (5.9 months; 95% CI, 4.5-8.8; P , .0001). On multivariate analysis, although late
relapse (hazard ratio [HR], 0.21; 95% CI, 0.13-0.34; P , .0001) was associated with
significantly lower mortality, the risk of mortality increased with age (HR, 1.25 per decade;
95% CI, 1.06-1.48; P 5 .009). This is the largest study to date to evaluate outcomes of DLBCL
patients relapsing after auto-HCT. Our study provides benchmarking for future trials of
chimeric antigen receptor T cells and other promising agents evaluating PR-OS after
auto-HCT.
Introduction
Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin lymphoma (NHL),
accounting for ;30% of all NHL cases in the United States. In 2019, it is estimated that there will be
22360 new cases diagnosed in the United States.1,2 Outcomes of DLBCL have improved since the
introduction of rituximab, with;60% of patients now cured with rituximab-containing first-line therapy.3,4
However, despite this progress, 40% to 50% of DLBCL patients either fail to achieve remission with
first-line therapy or relapse after achieving complete remission (CR). For relapsed/refractory DLBCL
patients, treatment with salvage chemotherapy followed by autologous hematopoietic cell trans-
plantation (auto-HCT) is potentially curative,5 although only ;50% of patients who receive second-line
salvage therapy demonstrate sufficient chemotherapy sensitivity to be candidates for auto-HCT.
Furthermore, of those who do undergo auto-HCT, ;50% will subsequently relapse. Contemporary
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registry data show that the relapse rate after auto-HCT has not
improved since the results of the Parma trial,6-8 despite various
strategies intended to improve outcomes.9-11
An expanding understanding of B-cell receptor biology in recent
years has led to rapid growth in the number of novel agents available
or undergoing evaluation for the treatment of relapsed/refractory
DLBCL.12-20 However, studies focusing on the outcomes specif-
ically of DLBCL patients relapsing after auto-HCT have been
sparse. In the recently published SCHOLAR-1 study of relapsed/
refractory DLBCL patients, median overall survival (OS) was 6.3
months. In that study, survival was measured starting from the time
of initiation of salvage therapy.21 However, SCHOLAR-1 included
patients who were primarily refractory to first- and second-line
therapies and only a smaller proportion of patients who relapsed/
progressed within 12 months after auto-HCT. There are 2 previously
published studies evaluating post–auto-HCT relapse outcomes, in
which a median OS post–auto-HCT relapse was reported to be in the
range of 9 to 10 months.22,23 However, both of those studies were
limited by small sample size and did not include patients treated in the
contemporary time period.
Therefore, we sought to evaluate the outcomes of DLBCL patients
relapsing after auto-HCT and determine the survival trends and
factors prognostic of post–auto-HCT survival. We hypothesized
that the outcomes of patients with DLBCL relapsing after auto-HCT
may have improved in more recent years because of the availability
of new/novel agents such as lenalidomide, ibrutinib, antibody/drug




Adult patients (age $18 years) with relapsed/refractory (de novo)
DLBCL who underwent auto-HCT between January 2006 and
December 2015 at 4 academic tertiary care medical centers
(Medical College of Wisconsin [Milwaukee, WI], The Ohio State
University [Columbus, OH], Washington University School of
Medicine [St. Louis, MO], and MD Anderson Cancer Center
[Houston, TX]) were identified using clinical and transplantation
databases. The Medical College of Wisconsin Scientific Review
Committee and institutional review boards at all 4 sites approved
this study. The study was performed in compliance with the
Declaration of Helsinki.
To be eligible for the study, patients must have experienced disease
relapse after auto-HCT (radiographic and/or histologically con-
firmed lymphoma relapse). Patients were selected after screening
for eligibility criteria. After a retrospective chart review, patients
were classified into 2 eras: era 1, 2006 to 2010 and era 2, 2011 to
2015. The year 2011 was chosen as the onset of the second era,
because most of the data on novel agents for treatment of relapsed/
refractory DLBCL came from around this time.12,13,16-18,20
Study end points and definitions
The primary end point was to determine post–auto-HCT relapse
OS (PR-OS) in lymphoma patients experiencing relapse or
progression after auto-HCT. The secondary end point was to
identify factors prognostic of PR-OS.
PR-OS was measured from the time of documentation of DLBCL
relapse or progression after auto-HCT to date of death or last
follow-up. Time to relapse was defined as the time from auto-HCT
to first documented evidence of DLBCL relapse or progression.
Patients who relapsed at or within 1 year of auto-HCT were
grouped into the early-relapse category, whereas those who
relapsed beyond 1 year constituted the late-relapse group. Tumor
assessment was performed according to individual center practices
and not reviewed centrally.
Statistical analysis
Demographic and disease characteristics were summarized using
descriptive statistics and compared between the cohorts using the
Wilcoxon rank-sum test for continuous and ordinal measures and x2
test for categorical outcomes. Patients were followed for survival
from the time of post–auto-HCT relapse to death or last follow-up.
Follow-up was administratively truncated at 6 years to better align
the 2 cohorts. Survival curves were estimated using the Kaplan-
Meier method and compared between groups via the log-rank test.
Cox regression was used for the multivariable analysis of survival.
The proportional hazards assumption was evaluated visually via
residual plots and formally by introducing time-dependent effects,
but no substantial deviations were found. The effect of the time-
dependent treatment-start variables was visualized using several
landmark times and analyzed in the Cox regression model as time-
dependent covariates. Analyses were performed using SAS software
(version 9.4; SAS Institute, Cary, NC).
Results
Patient characteristics
Of the 700 patients with de novo DLBCL who underwent auto-HCT
at 1 of 4 participating academic centers in the United States, 248
(35%) relapsed post–auto-HCT between 2006 and 2015. After
excluding patients who were chemotherapy refractory at auto-HCT
(n 5 20), 228 remained who were included in the analysis (era 1,
n 5 103; era 2, n 5 125), as shown in Figure 1. Patient
characteristics are listed in Table 1, with a breakdown between the
2 eras. Median age was 60 years, with male predominance (67%),
and for all patients, the stem cell source was a peripheral blood
hematopoietic progenitor cell graft. Median lines of therapy
pre–auto-HCT was 2 (range, 1-4). Median time to relapse post
auto-HCT was 6.1 months (range: 0.8–96.6 months). Median
follow-up of survivors post–auto-HCT relapse (with the clock
starting at relapse) was 39 months (range, 1-72 months). Of note,
the main clinicobiologic variables that seemed to differ between
DLBCL patients relapsing within 1 year after auto-HCT vs .1 year
were time from diagnosis to auto-HCT and remission status at auto-
HCT (supplemental Table 1).
Treatment at relapse
Salvage therapy at relapse after auto-HCT was based on physician
discretion at the individual academic centers (Table 1). Median lines
of therapy for DLBCL patients post–auto-HCT relapse was 1
(range, 0-9). The most common salvage therapies administered
were allogeneic HCT (21%), lenalidomide (18%), and clinical trial
participation (17%). Of note, although the predominant salvage
therapy post–auto-HCT relapse in era 1 was allogeneic HCT
(25%), lenalidomide (21%) was the most commonly used salvage
modality after auto-HCT relapse in era 2 (Table 1).
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PR-OS
Median PR-OS of all relapsed DLBCL patients after auto-HCT
(n 5 228) was 9.8 months (95% confidence interval [CI], 7-15),
with 1-year PR-OS of 46% (95% CI, 40-53), 3-year PR-OS of 33%
(95% CI, 26-39), and 5-year PR-OS of 28% (95% CI, 21-34;
Figure 2). When PR-OS was assessed based on remission status
at auto-HCT, median PR-OS for patients in CR was 17.8 months
(95% CI, 7.9-41.6), which was significantly longer than that for
patients who were in partial remission going into auto-HCT (7.1
months; 95% CI, 5.4-11; P 5 .01; Figure 3).
Median PR-OS was significantly better for patients undergoing
auto-HCT .1 year after DLBCL diagnosis (12.8 months; 95% CI,
7.6-24.9) vs within 1 year of diagnosis (6.3 months; 95% CI, 4.5-9.2;
P 5 .01; supplemental Figure 1) and for patients with late relapse
(56.4 months; 95%CI, 23.7-‘) vs early relapse (5.9 months; 95%CI,
4.5-8.8; P , .0001; Figure 4A). On detailed analysis of the timing of
relapse after auto-HCT, median PR-OS for patients relapsing within
3, 3 to 6, and 6 to 12months after auto-HCTwas 4.1 (95%CI, 3.2-5.2),
7.3 (95% CI, 3.8-11.5), and 17.8 months (95% CI, 7.2-43.2),
respectively (Figure 4B). For patients who relapsed .12 months
after auto-HCT, median PR-OS was 56.4 months (95% CI, 23.7 to
not reached).Of note, therewas no significant difference inmedian PR-OS
based on era of auto-HCT (era 1 vs era 2, 8 months; 95%CI, 5.9-22.3 vs
11 months; 95% CI, 6.6-17.9, respectively; P 5 .95; Figure 5).
Factors prognostic of PR-OS
Variables included in the multivariate analysis were era of auto-
HCT, age at auto-HCT, Eastern Cooperative Oncology Group
performance status at auto-HCT, disease status at auto-HCT, time
from auto-HCT to relapse, allogeneic HCT, and clinical trial
participation. On multivariate analysis (Table 2), although late
relapse (HR, 0.21; 95% CI, 0.13-0.34; P , .0001) was associated
with significantly lower mortality, the risk of mortality increased with
age (HR, 1.25 per decade; 95% CI, 1.06-1.48; P 5 .009). There
was some evidence that patients who were in CR at auto-HCT
had improved survival (HR, 0.75; 95% CI, 0.54-1.03; P 5 .07).
Of note, there was no significant effect of postrelapse clinical
trial participation (supplemental Figure 2A) or allogeneic HCT on
PR-OS (supplemental Figure 2B).
Subset analysis
Among the 228 patients relapsing after auto-HCT, 151 (66%)
relapsed at or within 1 year. There was no difference in median
PR-OS when comparing the early-relapse group between era 1 (5.3
months; 95% CI, 3.5-7.2) and era 2 (7.5 months; 95% CI, 4.7-11;
P 5 .65; supplemental Figure 3A). Seventy-seven patients (34%)
relapsed beyond 1 year after auto-HCT. There was no difference in
PR-OS when comparing the late-relapse group between era 1
(56.4 months; 95% CI, 23.5-‘) and era 2 (not reached; 95% CI,
15-‘; P 5 .95; supplemental Figure 3B). Although median PR-OS
was longer for patients who were in CR at auto-HCT in era 2 (21.7
months; 95% CI, 9.2-47.2) relative to era 1 (10.6 months; 95% CI,
5.7-71.8), the difference was not statistically significant (P 5 .78;
supplemental Figure 4A). There was no significant difference in
median PR-OS for patients who were in partial remission at auto-
HCT in era 1 (7.2 months; 95% CI, 4.3-17.4) vs era 2 (6.8 months;
95% CI, 5.1-12.8; P 5 .96; supplemental Figure 4B). Although
DLBCL patients who underwent auto-HCT at 4
transplant centers
N=700
Exclude patients who were
chemorefractory at auto-HCT (N=20)








Figure 1. CONSORT diagram.
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Table 1. Relapsed/refractory DLBCL patient characteristics
PEntire group (n 5 228) 2006-2010 (n 5 103) 2011-2015 (n 5 125)
Age at auto-HCT, y .96
Median 60 59 60
Range 25-77 32-77 25-77
Sex .85
Male 152 (67) 68 (66) 84 (67)
Female 76 (33) 35 (34) 41 (33)
ECOG PS at auto-HCT .22
0 36 (17) 17 (18) 19 (16)
1 173 (80) 76 (82) 97 (79)
2 6 (3) 0 6 (5)
Missing 13 10 3
DLBCL subtype .76
GCB 38/66 (58) 7/13 (54) 31/53 (58)
Non-GCB 28/66 (42) 6/13 (46) 22/53 (42)
DHL/THL 9/91 (10) 3/19 (16) 6/72 (8) .39
Time from diagnosis to auto-HCT, y .36
#1* 46 (20) 18 (17) 28 (22)
.1 184 (80) 85 (83) 97 (78)
Time from diagnosis to auto- HCT, mo .28
Median 20.1 21.4 18.6
Range 3.9-268 5.2-253 3.9-268
Lines of therapy before auto-HCT .71
Median 2.0 2.0 2.0
Range 1.0-4.0 1.0-4.0 1.0-4.0
Remission status at auto-HCT .80
CR 115 (50) 51 (50) 64 (51)
Partial remission 113 (50) 52 (50) 61 (49)
PB graft type 228 (100) 103 (100) 125 (100) —
Conditioning regimen .29
BEAM 210 (92) 97 (94) 113 (90)
Other 18 (8) 6 (6) 12 (10)
Timing of relapse after auto-HCT, y .53
#1 151 (66) 66 (64) 85 (68.0)
.1 77 (34) 37 (36) 40 (32.0)
Time from auto-HCT to relapse, mo .22
Median 6.2 6.4 6.1
Range 0.8-96.6 0.9-96.6 0.8-60.2
Salvage therapy post auto-HCT relapse
Lines of therapy
Median 1 1 1
Range 0-9 0-6 0-9
Lenalidomide 41/228 (18) 15/103 (15) 26/125 (21) .22
Ibrutinib 15/228 (7) 4/103 (4) 11/125 (9) .14
Data are n (%) unless otherwise indicated.
BEAM, carmustine, etoposide, cytarabine, and melphalan; ECOG, Eastern Cooperative Oncology Group; DHL, double-hit lymphoma; GCB, germinal center B-cell subtype; PS, performance
status; THL, triple-hit lymphoma.
*Patients with very early relapse after first-line therapy, those who achieved less than CR with first-line therapy, or those who were refractory to first-line therapy.
†Information regarding specific agents was available in 28 patients; of these, 21 patients received small-molecule–targeted therapies, 4 patients received drug-antibody conjugates, and 3
patients received other therapies (azacytadine, n 5 2; AZD9150, n 5 1).
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median PR-OS was longer in patients without double-hit lymphoma/
triple-hit lymphoma (n 5 91; 17.8 months; 95% CI, 9.1-41.6) vs
with double-hit lymphoma/triple-hit lymphoma (n 5 9; 5.5 months;
95% CI, 1.2-‘), the difference was not statistically significant
(P 5 .47), probably because of small sample size (supplemental
Figure 5).
Discussion
Prospective studies evaluating the outcomes of DLBCL patients
after auto-HCT relapse have not been performed. Here, we
performed a multicenter retrospective cohort study of DLBCL
patients relapsing after auto-HCT in the contemporaneous era and
made several important observations. First, there has been no
significant improvement in PR-OS in the most recent era. Second,
factors prognostic of significantly poor PR-OS include ad-
vanced age at auto-HCT and relapse within 1 year of auto-HCT.
Lastly, we could not discern the impact of clinical trial
participation or allogeneic HCT on PR-OS. In our study, the
rate of post–auto-HCT relapse was 35%, which is lower than
the 50% noted in the previous studies.5-7 This difference is likely
due to the fact that all patients in the current study received
rituximab-based frontline treatment and were chemotherapy
sensitive at auto-HCT.
With a better molecular understanding of DLBCL biology, a number
of novel agents have been introduced in recent years, which have
activity in relapsed/refractory DLBCL. These treatments include
immunomodulatory agents,12 BTK inhibitors,13 proteasome inhib-
itors,14 PI3K/AKT/mTOR pathway inhibitors,15,16 antibody-drug
Table 1. (continued)
PEntire group (n 5 228) 2006-2010 (n 5 103) 2011-2015 (n 5 125)
Checkpoint inhibitors 8/220 (4) 1/103 (1) 7/125 (6) .08
Allogeneic HCT 48/228 (21) 26/103 (25) 22/125 (18) .16
Clinical trials† 38/228 (17) 15/103 (15) 23/125 (19) .44
FU post–auto-HCT relapse, mo
Median 39 63 35
Range 1-72 5-72 1-72
Data are n (%) unless otherwise indicated.
BEAM, carmustine, etoposide, cytarabine, and melphalan; ECOG, Eastern Cooperative Oncology Group; DHL, double-hit lymphoma; GCB, germinal center B-cell subtype; PS,
performance status; THL, triple-hit lymphoma.
*Patients with very early relapse after first-line therapy, those who achieved less than CR with first-line therapy, or those who were refractory to first-line therapy.
†Information regarding specific agents was available in 28 patients; of these, 21 patients received small-molecule–targeted therapies, 4 patients received drug-antibody conjugates, and 3
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Figure 2. PR-OS of the entire population.
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conjugates,17 immune checkpoint inhibitors,18,19 BCL2 inhibitors,20
and others. However, despite the higher use of novel and investiga-
tional agents in the most recent era (55% vs 35%), median PR-OS
remained poor (9.8 months; 95% CI, 7-14.4). This observation is in
line with previously published studies22,23 showing continued poor
outcomes in DLBCL patients who progress after auto-HCT, even in
more recent years.
DLBCL patients relapsing within 1 year of auto-HCT had worse
prognosis, with a median PR-OS of 5.9 months, which has not
significantly improved in the most recent era. Our results are in line
with previously published studies including the post–auto-HCT
relapse group (defined by relapse within 1 year of auto-HCT) of the
SCHOLAR-121 study (6.2 months).21-23 On detailed analysis, we
noted that among patients relapsing within 1 year of auto-HCT, poor
outcomes were predominantly driven by patients relapsing within
6 months of auto-HCT. Alhough median PR-OS was slightly better
in patients relapsing within 6 months and 6 to 12 months after auto-
HCT relative to the previous study, where median PR-OS for
patients relapsing within 6 months and 6 to 12 months were 5.7 and
11.3 months, respectively23; outcomes continue to remain dismal in
this patient population. For patients relapsing .12 months after
auto-HCT, median PR-OS was significantly longer (56.4 months).
For this group of patients, a detailed discussion may be required
regarding consideration of alternatives to chimeric antigen receptor
(CAR) T-cell therapy, such as allogeneic HCT or nontransplanta-
tion/noncellular therapies. Median PR-OS was better in patients
who were in CR (relative to those in partial response) at the time of
auto-HCT, which is in line with previous studies.22,23 However, this
did not translate into a significant factor prognostic of PR-OS in the
multivariable analysis. The current study provides a breakdown of
data in a more granular way than in previous studies in the
post–auto-HCT relapse setting and should provide helpful bench-
marking for the post–auto-HCT relapse patients who make up
a significant proportion of the many CAR T-cell and related trials of
relapsed/refractory DLBCL currently taking place.
Allogeneic HCT provides a potentially curative option (via graft-
versus-lymphoma effect) for DLBCL patients who progress after
auto-HCT, with nearly 40% of carefully selected patients achieving
long-term remission.24 However, only ;20% of DLBCL patients
who fail auto-HCT ultimately proceed to allogeneic HCT,25 and
more importantly, the procedure has a high associated risk of
therapy-related complications; the associated rate of death un-
related to disease relapse is ;20% to 25% at 1 year.24,25 In our
study, we did not note any significant impact of allogeneic HCT on
PR-OS; however, the results need to be interpreted with caution,
given the small number of patients. Additionally, there could have
been significant selection bias for patients undergoing allogeneic
HCT, which could have altered the results.
Therapeutic T-cell engineering (eg, CAR T-cell therapy) has recently
garnered widespread interest because of the success of CD19
CAR therapy. CARs are synthetic receptors for antigens that
redirect the specificity and reprogram the function of the T cells into
which they are genetically introduced. Studies have shown very
good response rates with CAR T-cell therapy in the refractory
DLBCL patient population, with durable responses in a significant
subset of those achieving CR.26,27 However, only 2126 and
54 patients27 had undergone prior auto-HCT in these studies,
and outcomes of this particular patient population relative to those
of other relapsed/refractory groups are unclear. Nevertheless,
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Figure 3. PR-OS based on remission status at
auto-HCT.
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post–auto-HCT. The current study provides benchmarking for
future studies (post–CAR T-cell era) investigating PR-OS after
auto-HCT.
Given the retrospective nature of this study, our study has important
limitations. Because of the small proportion of patients receiving
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Figure 5. PR-OS based on timing of auto-HCT:
era 1 vs era 2.
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setting, further analysis of the impact of these agents on PR-OS
could not be performed. We did not have information on the revised
international prognostic index (secondary international prognostic
index) or c-MYC rearrangement at relapse, thereby precluding their
inclusion in the multivariable model. Response to the therapies
administered in the post–auto-HCT relapse setting was assessed by the
treating physician, and the information pertaining to assessment of
response (positron emission tomography vs computed tomography
scan) to these therapies was not available. Although type of imaging
modality (positron emission tomography vs computed tomography scan)
used could have had an impact on response to post–auto-HCT
relapse treatments, we believe that this would not ultimately have
had an impact on PR-OS. Lastly, outcomes of patients enrolled
in clinical trials may be difficult to interpret because of multiple
factors that can potentially influence enrollment, including Eastern
Cooperative Oncology Group performance status, organ function,
and nature of the trial (phase 1 vs 2), despite controlling for
patient-, disease-, and transplantation-related variables by using
landmark analysis and multivariable modeling.
Notwithstanding these limitations, this is the largest study to date to
evaluate the outcomes of DLBCL patients relapsing after auto-HCT.
DLBCL patients who relapse within 1 year of auto-HCT, and more
importantly within 6 months of auto-HCT, experience worse outcomes
and represent an urgent unmet need. CAR T-cell therapy may benefit
this patient population; however, additional data are needed to evaluate
the impact of CAR T-cell therapy for patients relapsing post–auto-
HCT. Our study provides benchmarking for future trials of CAR T cells
and other promising agents evaluating PR-OS after auto-HCT.
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